HER3 NSCLC Text Module

CME

Exploring the Clinical Landscape of Novel HER3-Targeted Treatments for Advanced NSCLC

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Released: November 06, 2023

Expiration: November 05, 2024

Rebecca S. Heist
Rebecca S. Heist, MD, MPH

Activity

Progress
1
Course Completed

References

  1. Haikala HM, Janne PA. Thirty years of HER3: from basic biology to therapeutic interventions. Clin Cancer Res. 2021;27:3528-3539.
  2. Uliano J, Corvaja C, Curigliano G, et al. Targeting HER3 for cancer treatment: a new horizon for an old target. ESMO Open. 2023;8:100790.
  3. Schoenfeld AJ, Chan JM, Kubota D, et al. Tumor analyses reveal squamous transformation and off-target alterations as early resistance mechanisms to first-line osimertinib in EGFR-mutant lung cancer. Clin Cancer Res. 2020;26:2654-2663.
  4. Kawano O, Sasaki H, Endo K, et al. ErbB3 mRNA expression correlated with specific clinicopathologic features of Japanese lung cancers. J Surg Res. 2008;146:43-48.
  5. Janne PA, Baik C, Su WC, et al. Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated non-small cell lung cancer. Cancer Discov. 2022;12:1598.
  6. Yu HA, Goto Y, Hayashi H, et al. HERTHENA-Lung01, a phase II trial of patritumab deruxtecan (HER3-DXd) in epidermal growth factor receptor–mutated non–small-cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitor therapy and platinum-based chemotherapy. J Clin Oncol. 2023;Epub ahead of print.
  7. Yu HA, Yang JC, Hayashi H, et al. HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic EGFR-mutated NSCLC. Future Oncol. 2023;19:1319-1329.
  8. Hayashi H, Yu HA, Baik C, et al. First report of cohort 3 and extended follow-up data from the U31402-A-U102 study of HER3-DXd in EGFR-mutated NSCLC. Presented at: 2023 Annual Meeting of the Japanese Society of Medical Oncology; March 16-18, 2023. Abstract PS1-2.
  9. Yu HA, Goto Y, Hayashi H, et al. Patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC following EGFR TKI and platinum-based chemotherapy: HERTHENA-Lung01. Presented at: 2023 World Conference on Lung Cancer; September 9-12, 2023. Abstract OA05.03.
  10. Johnson ML, Janne PA, Goto Y, et al. Intracranial efficacy of HER3-DXd in patients with previously treated advanced EGFR-mutated NSCLC: results from HERTHENA-Lung01. Presented at: 2023 European Society for Medical Oncology Congress; October 20-24, 2023. Abstract 1319MO.
  11. Zhang L, Ma Y, Zhao Y, et al. BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate, in patients with non-small cell lung cancer: updated results from first-in-human phase I study. Presented at: 2023 European Society for Medical Oncology Congress; October 20-24, 2023. Abstract 1316MO.
  12. Zhang L, Ma Y, Zhao Y, et al. BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic solid tumor: results from a first-in-human phase 1 study. Presented at: 2023 Annual Meeting of the American Society of Clinical Oncology; June 2-6, 2023. Abstract 3001.
  13. Zhao Y, Zhang L, Fang W, et al. SI-B001 plus chemotherapy in patients with locally advanced or metastatic EGFR/ALK wild-type non-small cell lung cancer: a phase II, multicenter, open-label study. Presented at: 2023 Annual Meeting of the American Society of Clinical Oncology; June 2-6, 2023. Abstract 9025.
  14. Fernandez-Cuesta L, Plenker D, Osada H, et al. CD74-NRG1 fusions in lung adenocarcinoma. Cancer Discov. 2014;4:415-422.
  15. Schram AM, Odintsov I, Espinosa-Cotton M, et al. Zenocutuzumab, a HER2xHER3 bispecific antibody, is effective therapy for tumors driven by NRG1 gene rearrangements. Cancer Discov. 2022;12:1233-1247.
  16. Schram A, Goto K, Kim DW, et al. Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC). Presented at: 2023 European Society for Medical Oncology Congress; October 20-24, 2023. Abstract 1315MO.
  17. Zhou Q, Wu YL, Li J, et al. Phase I study of SHR-A2009, a HER3-targeted ADC, in advanced solid tumors. Presented at: 2023 European Society for Medical Oncology Congress; October 20-24, 2023. Abstract 658MO.